(Q43072801)

13 November 2017

title

Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib (English)

1 reference

Carlo Gambacorti-Passerini

13 November 2017

1 reference

6

1 reference

13 November 2017

S Redaelli

1

1 reference

13 November 2017

F Boschelli

2

1 reference

13 November 2017

P Perini

3

1 reference

13 November 2017

A Pirola

4

1 reference

13 November 2017

M Viltadi

5

1 reference

13 November 2017

publication date

6 May 2010

1 reference

13 November 2017

1 reference

13 November 2017

volume

24

1 reference

13 November 2017

issue

6

1 reference

13 November 2017

page(s)

1223-1227

1 reference

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

13 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.79

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.79

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.79

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.79

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.79

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.79

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.79

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.79

21 January 2018

Identifiers

DOI

10.1038/LEU.2010.79

1 reference

Dimensions Publication ID

13 November 2017

1021742250

0 references

1 reference